Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Esketamine Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy RX501.105

    Esketamine Nasal Spray

    Customize your policy alerts

    Sign up for healthspring Policy RX501.105 alerts

    Get alerted when Policy RX501.105 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy provides HealthSpring guidance for coverage of esketamine nasal spray and directs providers and members to consult the applicable benefit plan, contract, and state regulations. The document window contains general medical-policy standards and an Ohio-specific exception, but no clinical coverage criteria.

    Policy Summary
    PayerHealthSpring
    PolicyEsketamine Nasal Spray
    Policy CodePolicy RX501.105
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for an initial 3-month treatment-resistant depression course when all coverage criteria are satisfied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age for covered treatment
    3 monthsInitial treatment-resistant depression authorization
    28 daysAcute suicidal ideation treatment period
    Spravato REMSRestricted program required
    6 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum antidepressant trial

    Covered and Non-Covered Uses

    Treatment-resistant depression initial authorization

    Covered when ALL of the following are met:

    Initial treatment-resistant depression authorization

    • Adult age and diagnosis: Individual is 18 years of age or older and meets DSM-5 criteria for a major depressive episode by structured clinical interview.Age ≥18
    • Qualifying depression severity: Current depressive episode is moderate or severe based on one of the specified rating scales.MADRS ≥28 OR HAMD ≥17 OR PHQ-9 ≥10 OR QIDS ≥11
    • Inadequate antidepressant response: Individual has tried and had an inadequate response to one qualifying antidepressant after an adequate trial.At least 6 weeks at generally accepted doses, or sufficient duration determined by the treating physician

      Qualifying antidepressants include an SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine.

    • Substance-use requirement: Individual does not have a current substance use disorder unless it is in remission.Complete abstinence for 1 month when in remission

    Major depressive disorder with acute suicidal ideation or behavior

    Covered when ALL of the following are met:

    Acute suicidal ideation or behavior

    • Individual is at least 18 years old.Age ≥18
    • Individual has major depressive disorder with acute suicidal ideation or behavior.
    • Individual receives esketamine nasal spray in conjunction with an oral antidepressant.Treatment period limited to 28 days

    Continuation therapy

    Covered when ALL of the following are met:

    Continuation treatment

    • Following at least 3 months of use, individual demonstrates improvement in depression symptoms on an appropriate depression rating scale.At least 3 months of prior use

      Appropriate scales include MADRS, HAM-D, PHQ-9, and QIDS.

    • Individual does not have a current substance use disorder.

    Initial therapy for treatment-resistant depression

    Esketamine nasal spray may be considered medically necessary for an initial authorization period of 3 months when all of the following are met.

    • Age and diagnosis: Individual is 18 years of age or older and meets DSM-5 criteria for major depressive disorder.≥18 years; DSM-5 major depressive disorder
    • Depression severity: The current depressive episode is moderate or severe based on one of the following rating-scale thresholds.MADRS ≥28 OR HAM-D ≥17 OR PHQ-9 ≥10 OR QIDS ≥11

      At least one rating-scale threshold must be met.

    • Prior antidepressant treatment: The individual has tried and had an inadequate response to one antidepressant agent, including an SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine, after an adequate trial.

    Continuation therapy

    Continuation of treatment after at least 3 months may be reauthorized when all of the following are met.

    • Clinical response: Depression symptoms have improved as evaluated with an appropriate depression rating scale.Improvement on MADRS, HAM-D, PHQ-9, QIDS, or another appropriate depression rating scale
    • Substance use disorder status: The individual does not have a current substance use disorder.

    Major depressive disorder with acute suicidal ideation or behavior

    Esketamine nasal spray may be considered medically necessary for a treatment period of 28 days when all of the following conditions are met.

    • Adult age: Individual is 18 years of age or older.≥18 years
    • Indication: Individual has major depressive disorder with acute suicidal ideation or behavior.
    • Concomitant antidepressant: Individual will receive esketamine nasal spray in conjunction with an oral antidepressant.

    For Ohio members, coverage may be required for an FDA-approved drug prescribed for an off-label use recognized as safe and effective in an applicable standard medical reference compendium or supported by medical literature. Medical-literature support requires evidence of safety and efficacy in two articles from major peer-reviewed professional medical journals; case studies or case series alone are not sufficient. Coverage is not required when the FDA has recognized the proposed use as contraindicated or when the drug is non-formulary.

    Esketamine nasal spray is considered experimental, investigational, and/or unproven for all uses other than the covered indications for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior.

    Esketamine nasal spray is considered experimental, investigational, and/or unproven when used outside the covered treatment requirements, including treatment-resistant depression criteria or the 28-day treatment period for major depressive disorder with acute suicidal ideation or behavior.

    Codes and Clinical Thresholds

    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCS
    G2082
    G2083
    J3490
    J0013
    Depression severity threshold
    InstrumentMontgomery-Asberg Depression Rating Scale (MADRS)
    Required scoreAt least 28
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentHamilton Rating Scale for Depression (HAMD)
    Required scoreAt least 17
    Policy use

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Treatment-Resistant Depression Authorization

    Obtain authorization for an initial 3-month treatment course when all applicable treatment-resistant depression criteria are satisfied and documented.

    • Member is 18 years or older.
    • DSM-5 major depressive episode is established by structured clinical interview.
    • Current episode is moderate or severe based on MADRS ≥28, HAMD ≥17, PHQ-9 ≥10, or QIDS ≥11.
    • One qualifying antidepressant trial produced an inadequate response.
    • No current substance use disorder, unless in remission with complete abstinence for at least 1 month.
    Prior Authorization

    Acute Suicidal Ideation Authorization

    A 28-day authorization may be issued for major depressive disorder with acute suicidal ideation or behavior when the indication-specific requirements are met.

    Policy Standards and Scope

    Requested drug therapy must be proven effective for the relevant diagnosis or procedure. The proposed dose, frequency, and duration must be consistent with recommendations from at least one authoritative source, such as FDA labeling, a nationally recognized drug compendium, peer-reviewed literature, professional guidelines, or CMS coverage policy.

    Clinical Terms and Measures

    Montgomery-Asberg Depression Rating Scale (MADRS)
    Description10-item scale used to evaluate the severity of depression
    Total score range0 to 60
    Severity ranges0-6 no depression; 7-19 mild; 20-34 moderate; 35-60 severe
    Hamilton Rating Scale for Depression (HAMD)
    Description17-item rating scale used to determine depression severity before, during, and after treatment
    Total score range0 to 52
    Severity ranges0-7 no depression; 8-16 mild; 17-23 moderate; 24 or greater severe

    Initial Authorization Criteria

    Treatment-resistant depression — initial authorization for 3 months

    Initial authorization for 3 months requires ALL of the following:

    Treatment-resistant depression

    • Individual is at least 18 years old and meets DSM-5 criteria for a major depressive episode by structured clinical interview.Age ≥18
    • Qualifying depression severity: Current depressive episode is moderate or severe based on one of the specified rating scales.MADRS ≥28 OR HAMD ≥17 OR PHQ-9 ≥10 OR QIDS ≥11
    • Prior antidepressant treatment: Individual has tried and had an inadequate response to one qualifying antidepressant after an adequate trial.

    Reauthorization Criteria

    Spravato continuation therapy — reauthorization after at least 3 months

    Reauthorization after at least 3 months requires ALL of the following:

    Continuation response and safety

    • Individual has improvement in depression symptoms as evaluated with an appropriate depression rating scale.At least 3 months of prior use

      Examples include MADRS, HAM-D, PHQ-9, and QIDS.

    • Individual does not have a current substance use disorder.

    Continuation authorization — criteria after at least 3 months of use

    Continuation after at least 3 months of use may be reauthorized when all conditions are met.

    Continuation authorization

    Required Prior Treatment

    StepRequired treatmentTrial requirement
    1Try one qualifying antidepressant before initial esketamine authorization: SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine.Inadequate response after at least 6 weeks at generally accepted doses, or a sufficient duration determined by the treating physician at generally accepted doses.
    StepRequired treatmentTrial requirement
    1Try one antidepressant agent before initial esketamine nasal spray authorization: SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine.Inadequate response after an adequate trial lasting at least 6 weeks at generally accepted doses, or a sufficient duration determined by the treating physician at generally accepted doses.

    Authorization Periods and Treatment Limits

    Initial treatment-resistant depression authorization
    MedicationEsketamine nasal spray (Spravato)
    IndicationTreatment-resistant depression in adults meeting the applicable criteria
    Initial authorization3 months
    Acute suicidal ideation or behavior treatment
    IndicationMajor depressive disorder with acute suicidal ideation or behavior
    Treatment period28 days; use beyond 4 weeks has not been systematically evaluated
    Administration and monitoring

    Administration and Dispensing Setting

    Billing Rule

    Use the required supervised site of care

    Esketamine must be dispensed and administered only in a medically supervised healthcare setting that monitors the individual, through the Spravato REMS program.

    • Dispensing pharmacies and healthcare settings must be certified through Spravato REMS.
    Policy Summary
    PayerHealthSpring
    PolicyEsketamine Nasal Spray
    Policy CodePolicy RX501.105
    Change TypeNo material change
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for an initial 3-month treatment-resistant depression course when all coverage criteria are satisfied.
    SourceLink
    On This Page
    Covered and Non-Covered UsesCodes and Clinical ThresholdsAuthorization, Documentation, and Denial RisksPolicy Standards and ScopeClinical Terms and MeasuresInitial Authorization CriteriaReauthorization CriteriaRequired Prior TreatmentAuthorization Periods and Treatment LimitsAdministration and Dispensing Setting
    At least 6 weeks at generally accepted doses, or sufficient duration determined by the treating physician at generally accepted doses
  1. Substance use disorder status: The individual does not have a current substance use disorder, or the substance use disorder is in remission with complete abstinence for 1 month.Complete abstinence for 1 month if in remission
  2. Qualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentPatient Health Questionnaire 9 (PHQ-9)
    Required scoreAt least 10
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentQuick Inventory of Depressive Symptomatology (QIDS)
    Required scoreAt least 11
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentMontgomery-Asberg Depression Rating Scale (MADRS)
    Required scoreAt least 28
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentHamilton Rating Scale for Depression (HAM-D)
    Required scoreAt least 17
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentPatient Health Questionnaire 9 (PHQ-9)
    Required scoreAt least 10
    Policy useQualifying threshold for moderate or severe current depression
    Depression severity threshold
    InstrumentQuick Inventory of Depressive Symptomatology (QIDS)
    Required scoreAt least 11
    Policy useQualifying threshold for moderate or severe current depression
  3. Member is 18 years or older.
  4. Major depressive disorder with acute suicidal ideation or behavior is documented.
  5. Esketamine is administered with an oral antidepressant.
  6. Prior Authorization

    Reauthorization After Initial Course

    After at least 3 months of treatment, reauthorization requires documented clinical benefit and absence of a current substance use disorder.

    • Improvement in depressive symptoms is demonstrated using an appropriate scale, such as MADRS, HAM-D, PHQ-9, or QIDS.
    • Reauthorization is not supported with a current substance use disorder.
    Prior Authorization

    Initial Authorization Requirements

    For treatment-resistant depression, authorize an initial treatment period of 3 months only when the documented diagnosis, severity, treatment history, and safety criteria are met.

    • Initial authorization period: 3 months.
    • DSM-5 major depressive disorder is documented.
    • Moderate or severe episode is supported by MADRS ≥28, HAM-D ≥17, PHQ-9 ≥10, or QIDS ≥11.
    • Inadequate response to one qualifying antidepressant trial is documented.
    • No current substance use disorder unless in remission.
    Prior Authorization

    Continuation Authorization

    Continuation after at least 3 months requires documented symptom improvement and confirmation that the member does not have a current substance use disorder.

    • Use an appropriate depression rating scale to evaluate response.
    • Retain supporting clinical records for the continuation decision.
    Prior Authorization

    28-Day Acute Indication Authorization

    For major depressive disorder with acute suicidal ideation or behavior, authorize treatment for a maximum treatment period of 28 days when the indication requirements are met.

    • Member is 18 years or older.
    • Acute suicidal ideation or behavior is documented.
    • Treatment is given in conjunction with an oral antidepressant.
    • Use beyond 4 weeks has not been systematically evaluated.
    Step Therapy

    Prior Antidepressant Trial

    Before initial authorization for treatment-resistant depression, document an inadequate response to at least one qualifying antidepressant agent.

    • Qualifying agents include an SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine.
    • The trial must last at least 6 weeks at generally accepted doses, or for a sufficient duration at generally accepted doses as determined by the treating physician.
    • Record the agent, dose, duration, and inadequate response.
    Billing Rule

    Verify Member Benefit Requirements

    Verify the member’s benefit plan, summary plan description, or contract before treatment or billing. The member contract governs if it conflicts with this medical policy.

    • Check applicable exclusions, dollar caps, limitations, conditions, and authorization requirements.
    • Consider applicable state regulations and benefit-plan provisions.
    Note

    Ohio Off-Label Literature Support

    For Ohio members, off-label coverage may be required when the use is recognized as safe and effective in an adopted compendium or supported by medical literature meeting the statutory standard.

    • Medical-literature support requires two articles from major peer-reviewed professional medical journals documenting safety and efficacy.
    • Accepted evidence may include randomized, double-blind, placebo-controlled clinical trials; case studies or case series alone are insufficient.
    • Examples of qualifying journals include JAMA, New England Journal of Medicine, and Lancet.
    Documentation Required

    Initial Clinical Documentation

    For initial treatment-resistant depression authorization, submit clinical documentation supporting age, diagnosis, episode severity, treatment history, and substance-use status.

    • Age: 18 years or older.
    • DSM-5 major depressive episode established by structured clinical interview.
    • Severity score: MADRS ≥28, HAMD ≥17, PHQ-9 ≥10, or QIDS ≥11.
    • Qualifying antidepressant trial and inadequate response.
    • Current substance use disorder is absent or documented as in remission with at least 1 month of complete abstinence.
    Documentation Required

    Continuation Response Documentation

    For continuation authorization, document measurable improvement in depressive symptoms using an appropriate depression rating scale and update substance-use status.

    • Acceptable examples include MADRS, HAM-D, PHQ-9, and QIDS.
    • Include the relevant score, comparison with baseline when available, treatment response, and supporting clinical records.
    • Confirm no current substance use disorder.
    Documentation Required

    Acute Suicidality Documentation

    For the acute suicidal ideation or behavior indication, document the diagnosis, age, acute suicidal ideation or behavior, and concurrent oral-antidepressant treatment.

    • Member is 18 years or older.
    • Major depressive disorder with acute suicidal ideation or behavior is documented.
    • Esketamine is being used with an oral antidepressant.
    • Limit authorization to the 28-day treatment period.
    Documentation Required

    Initial Documentation for CMS Criteria

    For the initial treatment-resistant depression indication, retain records demonstrating the DSM-5 diagnosis, episode severity, and qualifying antidepressant history.

    • Document MADRS, HAM-D, PHQ-9, or QIDS severity results.
    • Document the qualifying antidepressant, generally accepted dose, trial duration, and inadequate response.
    • Document substance-use status and remission, if applicable.
    Documentation Required

    Continuation Documentation

    For continuation authorization, submit evidence of symptom improvement after at least 3 months and the clinical records supporting continued treatment.

    • Use an appropriate depression rating scale, such as MADRS, HAM-D, PHQ-9, or QIDS.
    • Document ongoing treatment response and absence of a current substance use disorder.
    Documentation Required

    Acute Indication Documentation

    For the 28-day acute indication, provide indication-specific records rather than relying solely on a treatment-resistant depression history.

    • Document age of at least 18 years.
    • Document major depressive disorder with acute suicidal ideation or behavior.
    • Document concurrent oral-antidepressant therapy.
    Denial Risk

    Ohio Contraindication or Non-Formulary Limitation

    Ohio coverage is not required when the FDA has recognized the use as contraindicated or when the drug is non-formulary.

    • The Ohio off-label coverage provision does not override an FDA-recognized contraindication.
    • Coverage is not required for non-formulary drugs.
    • Also verify the member contract and applicable benefit limitations.
    Denial Risk

    Initial Criteria Not Met

    Deny or pend initial treatment-resistant depression authorization when any required clinical or documentation criterion is not met.

    • Member is younger than 18.
    • DSM-5 major depressive episode is not established.
    • Depression severity does not meet MADRS, HAMD, PHQ-9, or QIDS thresholds.
    • No qualifying inadequate-response antidepressant trial is documented.
    • Current substance use disorder is present and not in remission.
    • Required clinical records are incomplete.
    Denial Risk

    Continuation Criteria Not Met

    Deny continuation when the member has not demonstrated improvement after at least 3 months or has a current substance use disorder.

    • No improvement is documented on an appropriate depression rating scale.
    • Response documentation or supporting clinical records are absent or inadequate.
    • A current substance use disorder is present.
    Denial Risk

    Use Outside Covered Indications

    Esketamine is experimental, investigational, and/or unproven in situations outside the covered treatment-resistant depression and 28-day acute suicidal ideation or behavior indications.

    • Do not approve uses that do not meet the specified diagnosis, severity, treatment-history, continuation, or acute-indication criteria.
    • Benefit-plan exclusions and limitations may independently apply.
    Denial Risk

    REMS or Supervised-Setting Failure

    Administration must comply with the Spravato REMS and medically supervised-setting requirements. Failure to meet these safeguards creates a denial and safety risk.

    • Esketamine is dispensed and administered only in a medically supervised healthcare setting with monitoring.
    • The dispensing pharmacy and healthcare setting must be REMS-certified.
    • Inform the member about sedation, dissociation, serious adverse outcomes, and monitoring requirements.
    • Enroll all individuals in the required registry.
    Denial Risk

    Failure to Meet Initial Treatment Criteria

    Deny initial authorization when the member does not satisfy the required treatment-resistant depression criteria or the submitted documentation is insufficient.

    • No documented DSM-5 major depressive disorder.
    • Episode severity is below the specified rating-scale thresholds.
    • No inadequate response to one qualifying antidepressant trial, or the trial was shorter than 6 weeks without sufficient physician-supported duration.
    • Current substance use disorder is not in remission.
    Denial Risk

    Failure to Meet Continuation Criteria

    Deny reauthorization when continuation requirements are not met after at least 3 months of use.

    • No documented improvement in depressive symptoms using an appropriate rating scale.
    • Supporting clinical records are missing or do not establish benefit.
    • Current substance use disorder is present.
    Denial Risk

    Acute Suicidal Ideation or Behavior Criteria Not Met

    Deny the 28-day acute indication when any indication-specific requirement is absent or treatment exceeds the supported period.

    • Member is younger than 18.
    • Major depressive disorder with acute suicidal ideation or behavior is not documented.
    • Esketamine is not administered with an oral antidepressant.
    • Requested treatment extends beyond the 28-day period; use beyond 4 weeks has not been systematically evaluated.
    Denial Risk

    Uncovered or Unproven Use

    All other uses of esketamine nasal spray are considered experimental, investigational, and/or unproven under this policy.

    • This includes uses that do not meet the covered treatment-resistant depression criteria, continuation criteria, or 28-day acute suicidal ideation or behavior criteria.
    • Apply applicable member-contract exclusions and limitations.
    Patient Health Questionnaire 9 (PHQ-9)
    DescriptionNine-question instrument for screening, diagnosing, monitoring, and measuring depression severity
    Total score range0 to 27
    Severity ranges0-4 none to minimal; 5-9 mild; 10-14 moderate; 15-19 moderately severe; 20-27 severe
    Quick Inventory of Depressive Symptomatology (QIDS)
    Description16-item instrument derived from the 30-item Inventory of Depressive Symptomatology to assess depressive symptom severity
    Total score range0 to 27
    Severity ranges0-5 no depression; 6-10 mild; 11-15 moderate; 16-20 severe; 21 or greater very severe
    Assessment of suicidal ideation or behavior
    Primary instrumentMini-International Neuropsychiatric Interview, including affirmative responses to questions about suicidal thoughts and intent in the past 24 hours
    Additional instrumentsBeck Scale for Suicide Ideation and Columbia-Suicide Severity Rating Scale
    Other recognized scaleSuicide Ideation Scale
    Treatment-resistant depression
    DefinitionDepression that does not respond satisfactorily to adequate treatment
    Generally accepted standardFailure of 2 or more antidepressant treatment attempts
    Treatment standardEach attempt uses an adequate dose and duration
    Major depressive episode
    Required symptomsFive or more symptoms, including depressed mood or anhedonia
    DurationTwo weeks
    Clinical impactSymptoms cause clinically significant distress or functional impairment
    ExclusionsNot attributable to a substance or medical condition, not better explained by psychotic illness, and no history of manic or hypomanic episode
    Stable remission
    MeasureMADRS total score
    Score requirement12 or less
    Time requirementAt least 3 of the last 4 weeks during maintenance treatment
    Stable response
    MeasureMADRS total score
    Required reductionAt least 50% reduction
    Time and qualificationReduction during the last 2 weeks of optimization without meeting remission criteria
    MADRS
    AcronymMADRS
    Full nameMontgomery-Åsberg Depression Rating Scale
    PurposeMeasure of depressive symptom severity
    CGI-SS-r
    Full nameClinical Global Impression of Suicidal Severity - Revised
    Assessment typeOne-item, clinician-rated assessment
    MeasuresCurrent suicidal ideation and behavior severity; scores range from 0 to 6, with higher scores indicating greater severity
    SOC
    AcronymSOC
    Core treatmentInitial inpatient psychiatric hospitalization and a newly initiated or optimized oral antidepressant
    Antidepressant useOral antidepressant monotherapy or antidepressant therapy with augmentation
    SDLP
    AcronymSDLP
    Full nameStandard deviation of the lateral position
    UseMeasure of driving impairment
    TRD
    AcronymTRD
    Full nameTreatment-resistant depression
    MeaningDepression that has not responded satisfactorily to adequate treatment
    Adequate antidepressant trial
    Minimum durationAt least 6 weeks
    Dosing standardGenerally accepted doses
    Alternative duration standardSufficient duration as determined by the treating physician at generally accepted doses
    Substance use disorder remission
    RequirementComplete abstinence
    Duration1 month
    Policy applicationDefines remission of a substance use disorder for purposes of the policy
    At least 6 weeks at generally accepted doses, or sufficient duration determined by the treating physician

    Qualifying agents include an SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine.

  7. Substance-use requirement: Individual does not have a current substance use disorder unless it is in remission.Complete abstinence for 1 month when in remission
  8. Acute suicidal ideation or behavior — initial authorization for 28 days

    Initial authorization for 28 days requires ALL of the following:

    Acute suicidal ideation or behavior

    • Individual is at least 18 years old.Age ≥18
    • Individual has major depressive disorder with acute suicidal ideation or behavior.
    • Individual receives esketamine nasal spray in conjunction with an oral antidepressant.

    Initial treatment-resistant depression authorization — 3-month criteria

    Treatment-resistant depression coverage may be considered for an initial authorization period of 3 months when all criteria are met.

    Initial treatment-resistant depression authorization

    • Member is 18 years of age or older and meets DSM-5 criteria for major depressive disorder.≥18 years
    • Depression severity: The current depressive episode is moderate or severe based on one specified rating-scale threshold.MADRS ≥28 OR HAM-D ≥17 OR PHQ-9 ≥10 OR QIDS ≥11
    • Prior antidepressant treatment: The individual has tried and had an inadequate response to one antidepressant agent, including an SSRI, SNRI, tricyclic antidepressant, bupropion, or mirtazapine, after an adequate trial.Generally at least 6 weeks at generally accepted doses, or sufficient duration determined by the treating physician at generally accepted doses
    • Substance use disorder status: The individual does not have a current substance use disorder, or the substance use disorder is in remission with complete abstinence for 1 month.Complete abstinence for 1 month if in remission

    Acute suicidal ideation authorization — 28-day criteria

    Coverage for major depressive disorder with acute suicidal ideation or behavior may be considered for 28 days when all criteria are met.

    Acute suicidal ideation or behavior

    • Individual is at least 18 years of age.≥18 years
    • Individual has major depressive disorder with acute suicidal ideation or behavior.
    • Individual will receive esketamine nasal spray in conjunction with an oral antidepressant.
  9. Depression symptoms have improved on an appropriate depression rating scale.At least 3 months of prior use
  10. The individual does not have a current substance use disorder.
  11. 84 mg twice weekly for 4 weeks, reducible to 56 mg twice weekly based on tolerability; administered in a medically supervised setting through the Spravato REMS program
    Initial authorization period
    MedicationEsketamine nasal spray
    Authorization phaseInitial treatment for treatment-resistant depression
    Authorization period3 months
    Acute suicidal ideation treatment period
    MedicationEsketamine nasal spray
    IndicationMajor depressive disorder with acute suicidal ideation or behavior
    Treatment period28 days